Skip to main content
Premium Trial:

Request an Annual Quote

Meso Scale Tech, Rigel, Amersham Among Recent US Patent Winners

Premium

Meso Scale Technologies has been awarded US Patent No. 6,919,173, "Assay buffer, compositions containing the same, and methods of using the same."

Inventors listed on the patent are Michael Tsionky, Eli Glazer, Selen Altunata, George Sigal, Jonathan Leland, Mark Billadeau, Svetlana Leytner, Mark Martin, and Larry Helms.

According to its abstract, the patent protects compositions, reagents, kits, systems, system components, and methods for performing assays. More particularly, the invention relates to the use of novel combinations of reagents to provide improved assay performance, the abstract states.


Rigel Pharmaceuticals has been awarded US Patent No. 6,919,184, "Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents."

Inventors listed on the patent are Sarkiz Issakani, Jianing Huang, Julie Sheung, and Todd Pray.

According to its abstract, the patent protects methods and compositions for assaying for ubiquitin agents that are enzymatic components of ubiquitin-mediated proteolysis and, more particularly, methods and compositions for assaying for agents that modulate the activity of such ubiquitin agents.


Amersham (GE Healthcare) has been awarded US Patent No. 6,919,186, "Fluorescent proteins."

Inventors listed on the patent are Simon Stubbs, Anne Jones, Nigel Michael, and Nicholas Thomas.

According to its abstract, the patent protects novel engineered derivatives of green fluorescent protein (GFP) which have an amino acid sequence which is modified by amino acid substitution compared with the amino acid sequence of wild-type GFP. The modified GFPs exhibit enhanced fluorescence relative to wild-type GFP when expressed in non-homologous cells at temperatures above 30° Celsius, and when excited at about 490 nm compared to the parent proteins, i.e. wild-type GFP. An example of a preferred protein is F64L-S175G-E222G-GFP, the abstract states. The modified GFPs provide a means for detecting GFP reporters in mammalian cells at lower levels of expression and/or increased sensitivity relative to wild-type GFP. This greatly improves the usefulness of fluorescent proteins in studying cellular functions in living cells, the abstract states.


The Children's Hospital of Philadelphia has been awarded US Patent No. 6,919,208, "Methods and compositions for enhancing the delivery of a nucleic acid to a cell."

Inventors listed on the patent are Robert Levy, Peter Jones, and Quanyi Li.

According to its abstract, the patent protects methods and compositions useful for enhancing the efficiency of delivery of a nucleic acid to a cell. Preferably the cell is a mammalian cell, the abstract states. The method comprises providing to a cell an agent capable of enhancing the cytoskeletal permissiveness of the cell for transfection, and providing to the cell a nucleic acid delivery system for the transfection of the cell, whereby the efficiency of delivery of a nucleic acid to the cell is enhanced. Compositions and kits for enhancing the efficiency of delivery of a nucleic acid to a cell are also included, the abstract states.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.